Roundview Capital LLC Grows Holdings in Boston Scientific Corporation $BSX

Roundview Capital LLC raised its position in Boston Scientific Corporation (NYSE:BSX) by 143.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,059 shares of the medical equipment provider’s stock after purchasing an additional 2,980 shares during the period. Roundview Capital LLC’s holdings in Boston Scientific were worth $543,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. HM Payson & Co. lifted its holdings in Boston Scientific by 1.4% in the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after purchasing an additional 98 shares in the last quarter. IVC Wealth Advisors LLC increased its stake in shares of Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 102 shares during the last quarter. Park Square Financial Group LLC increased its stake in shares of Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after acquiring an additional 103 shares during the last quarter. HHM Wealth Advisors LLC increased its stake in shares of Boston Scientific by 13.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after acquiring an additional 103 shares during the last quarter. Finally, Rise Advisors LLC increased its stake in shares of Boston Scientific by 13.9% during the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 103 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $121.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 1st. Robert W. Baird upped their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Truist Financial upped their price objective on shares of Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Leerink Partners upped their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Finally, Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $120.71.

Boston Scientific Stock Down 0.9%

BSX opened at $95.86 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The firm has a 50 day moving average price of $102.53 and a 200 day moving average price of $101.99. The company has a market cap of $142.05 billion, a PE ratio of 57.06, a price-to-earnings-growth ratio of 2.33 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the company earned $0.62 earnings per share. Boston Scientific’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $17,972,457 over the last three months. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.